1. Home
  2. AUROW vs TGTX Comparison

AUROW vs TGTX Comparison

Compare AUROW & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aurora Innovation Inc. Warrant

AUROW

Aurora Innovation Inc. Warrant

HOLD

Current Price

$0.28

Market Cap

0.0

Sector

Technology

ML Signal

HOLD

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

HOLD

Current Price

$30.21

Market Cap

5.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AUROW
TGTX
Founded
2017
1993
Country
United States
United States
Employees
1800
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
5.5B
IPO Year
N/A
1995

Fundamental Metrics

Financial Performance
Metric
AUROW
TGTX
Price
$0.28
$30.21
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$54.75
AVG Volume (30 Days)
137.0K
1.6M
Earning Date
04-30-2025
11-03-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
2.78
Revenue
N/A
$531,898,000.00
Revenue This Year
N/A
$87.88
Revenue Next Year
N/A
$48.75
P/E Ratio
N/A
$11.21
Revenue Growth
N/A
100.88
52 Week Low
$2.09
$25.28
52 Week High
$3.00
$46.48

Technical Indicators

Market Signals
Indicator
AUROW
TGTX
Relative Strength Index (RSI) 38.95 41.29
Support Level $0.28 $30.40
Resistance Level $0.34 $32.30
Average True Range (ATR) 0.03 1.10
MACD 0.01 -0.01
Stochastic Oscillator 21.86 22.12

Price Performance

Historical Comparison
AUROW
TGTX

About AUROW Aurora Innovation Inc. Warrant

Aurora Innovation Inc delivers self-driving technology safely, quickly, and broadly. The Aurora Driver is a self-driving system designed to operate multiple vehicle types, from freight-hauling trucks to ride-hailing passenger vehicles. It underpins Aurora Horizon and Aurora Connect, its driver-as-a-service products for trucking and ride-hailing. The Company is developing the Aurora Driver, a scalable suite of self-driving hardware, software, and data services designed as a platform to adapt and interoperate among vehicle types and applications.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.

Share on Social Networks: